Request Demo

Last update 02 Aug 2026

Rizatriptan Benzoate

Last update 02 Aug 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

RIZATRIPTAN, INT-0008, INT-0008/2007

+ [10]

Target

5-HT1B receptor x 5-HT1D receptor

Action

agonists

Mechanism

5-HT1B receptor agonists(Serotonin 1b (5-HT1b) receptor agonists), 5-HT1D receptor agonists(Serotonin 1d (5-HT1d) receptor agonists)

Therapeutic Areas

Nervous System Diseases

Active Indication

Migraine Disorders

Inactive Indication

Acute migraineMigraine With AuraMigraine Without Aura+ [1]

Originator Organization

Merck Sharp & Dohme Corp.

Active Organization

Eisai Co., Ltd.

Sichuan Zitonggong Pharmaceutical Co., Ltd.

Organon & Co.

+ [3]

Inactive Organization

Gensco Pharma LLC

License Organization

IntelGenx Corp.

Exeltis Pharmaceuticals Holding SL

Aquestive Therapeutics, Inc.

+ [5]

Drug Highest PhaseApproved

First Approval Date

Mexico (21 Jan 1998),

Migraine Disorders

Regulation-

Structure/Sequence

Molecular FormulaC22H25N5O2

InChIKeyJPRXYLQNJJVCMZ-UHFFFAOYSA-N

CAS Registry145202-66-0

Clinical Trials associated with Rizatriptan Benzoate

JPRN-UMIN000061371

/ Active, not recruitingPhase 4IIT

Triptans and lasmiditan in patients with migraine attacks associated with neurodevelopmental disorders

Start Date27 Mar 2025

Sponsor / Collaborator-

NCT06473597

/ RecruitingPhase 4IIT

A Comparison of Rimegepant Orally Disintegrating Tablet (Nurtec ODT) to Rizatriptan Benzoate Orally Disintegrating Tablet (Maxalt MLT-ODT) in Adult Patients Presenting to the ED With Migraine Headache: Randomized, Double-Blind, Clinical Trial

Rimegepant (Nurtec) is an orally administered small molecule CGRP receptor antagonist with efficacy in the acute treatment of migraine. Rizatriptan benzoate (MAXALT), is a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist. Rizatriptan binds with high affinity to human cloned 5-HT1B and 5-HT1D receptors which leads to activation of these receptors results in cranial vessel constriction, inhibition of neuropeptide release and reduced transmission in trigeminal pain pathways with resultant relieve of the headache.
Teh investigators hypothesize that the administration of Rimegepant ODT would provide better analgesic efficacy than Rizatriptan ODT with respect to analgesic efficacy at 60 min and 120 minutes in ED patients with acute headache.
This is a prospective, randomized, double-blind superiority trial evaluating and comparing analgesic efficacy and safety of Rimegepant ODT 75 mg to Rizatriptan ODT 10 mg in adult patients presenting to the Emergency Department of Maimonides Medical Center with acute migraine headache.

Start Date01 Sep 2024

Sponsor / Collaborator

Maimonides Medical Center

IRCT20230913059428N1

/ SuspendedPhase 3IIT

A clinical trial of sublingual Rizatriptan versus oral Betahistin in acute phase treatment of vertigo in patients suffering from vestibular migraine

Start Date23 Oct 2023

Sponsor / Collaborator

Tabriz University of Medical Sciences

100 Clinical Results associated with Rizatriptan Benzoate

100 Translational Medicine associated with Rizatriptan Benzoate

100 Patents (Medical) associated with Rizatriptan Benzoate

1,484

Literatures (Medical) associated with Rizatriptan Benzoate

01 Jul 2026·HEADACHE

Comparative analysis of real‐world acute prescription migraine therapy outcomes: Insights from the HeAD – US study

Article

Author: Cadiou, François ; Ezzati, Ali ; Lipton, Richard B. ; Urani, Alexandre ; Fanning, Kristina M. ; Khorsand, Babak ; Teichrow, Devin

Abstract:

Background:

Triptans have long served as the primary acute migraine treatment, whereas gepants represent a newer, non‐vasoconstrictive alternative. Although clinical trials have explored efficacy within each class, head‐to‐head studies are lacking, and real‐world data on optimal treatment response and patient‐level predictors of outcomes remain limited. We leverage cross‐sectional data from the Headache Assessment via Digital Platform in United States study to conduct real‐world comparisons of triptans and gepants for 2‐h pain freedom (2hPF) and 24‐h pain relief (24hPR), and to identify demographic, clinical, and treatment‐related predictors of these outcomes.

Methods:

Head–US is a survey conducted between September and December of 2023 among users of the Migraine Buddy application (Aptar, Crystal Lake, IL). Eligible participants completed the survey, met ICHD‐3 criteria for migraine, and reported using acute monotherapy with gepants or a triptan. Primary outcomes, 2hPF and 24hPR posttreatment, were assessed using the Migraine Treatment Optimization Questionnaire‐6 item. Potential predictors included demographic factors, clinical measures, and treatment‐related factors.

Results:

Among 1570 eligible respondents, 567 used gepants and 1003 used a triptan. Mean age was 43.35 years (standard deviation = 13.04), and 91.2% were female. Gepant users demonstrated 36% higher odds of achieving 24hPR compared to triptan users (adjusted odds ratio = 1.36, 95% confidence interval: 1.09–1.71), although there were no significant differences the 2hPF outcome. Reduced odds of adequate 2hPF were associated with higher migraine symptom severity, high‐frequency episodic migraine, chronic migraine, severe pain intensity, and severe migraine disability. Odds of achieving 24hPR were reduced in those with higher attack frequency, severe migraine disability, and preventive medication use. Predictors of treatment response were similar in the pooled sample and in those using gepants and in those using triptans.

Conclusion:

In this large, real‐world cohort, triptans and gepants did not significantly differ for 2hPF, but gepants demonstrated a significant advantage for 24hPR. Clinical features such as symptom severity, headache frequency, disability, and comorbid treatment burden were important predictors of treatment response. These findings support the need for larger, head‐to‐head clinical trials definitively comparing these medication classes for migraine management and may inform personalized selection of acute migraine therapies in clinical practice.

01 Jun 2026·JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Eco-friendly appraised HPTLC strategy for the simultaneous determination of the newly approved meloxicam and rizatriptan mixture in their formulation

Article

Author: Emran, Talha Bin ; Attia, Sabry M ; Mohamed, Ahmed R ; Ali, Akbar ; Taha, Asmaa M ; Darweish, Eman

Migraine is recognized as a major neurological disorder characterized by substantial global prevalence, affecting more than one billion individuals worldwide. In 2025, the FDA approved a novel fixed-dose mixture of rizatriptan (RIZ) and meloxicam (MEL) for managing acute migraine. In response, an affordable and sensitive TLC-densitometric strategy was developed for determining MEL and RIZ concurrently in their pure powders and recently approved formulation. The separation process was achieved on a 60F₂₅₄ silica gel stationary phase employing a moving phase of methanol, ethyl acetate, and 25% aqueous ammonia (9:1:0.05, by volume). The medications were UV-scanned at 254.0 nm. Key chromatographic parameters influencing strategy performance were systematically investigated and optimized. Our strategy was fully validated, consistent with ICH standards, and demonstrated satisfactory linearity over concentration ranges of 2-12 μg/band for MEL and 1-6 μg/band for RIZ, along with good accuracy, robustness, precision, and selectivity, enabling reliable quantification without intrusion from common excipients. Furthermore, the environmental sustainability and overall analytical performance of our strategy were comprehensively assessed utilizing multiple appraisal tools, confirming its favorable environmental profile, balanced analytical performance, and practical applicability compared with previously documented methods. Compared with previously published LC methods, particularly UPLC, our strategy requires lower solvent consumption and reduced energy demand and generates less analytical waste owing to the simultaneous analysis of multiple samples on a single plate, while also offering greater operational simplicity. The ability to simultaneously estimate all analytes in a single TLC run cheaply renders our strategy efficient and well-suited for regular QC testing.

12 May 2026·NEUROLOGY

Acute Environmental Triggers and Intermediate-Term Modulators of Emergency Migraine-Related Health Care Encounters

Article

Author: Novack, Victor ; Peles, Ido ; Gordon, Michal ; Sarov, Batia ; Novack, Lena ; Ifergane, Gal

BACKGROUND AND OBJECTIVES:

Migraine activity is shaped not only by the biological vulnerability but also by environmental factors that may influence susceptibility and contribute to fluctuations in migraine occurrence, although the evidence remains inconsistent. We aimed to evaluate the intermediate-term and short-term effects of environmental exposures on migraine activity and to examine a conceptual layered model comprising biological vulnerability, intermediate-term environmental modulators, and acute triggers.

METHODS:

We conducted a population-based case-crossover study among patients with migraine identified from the Negev Migraine Cohort (2000-2023), using electronic medical records from Clalit Health Services and Soroka University Medical Center. Eligible participants were adult patients (≥18 years) residing in Be'er Sheva, Israel, with migraine diagnoses or triptan prescriptions. Daily exposure to air pollutants and meteorologic conditions were obtained from fixed monitoring stations. Outcomes were emergency migraine-related encounters as a marker of triggered events and quarterly triptan use as a marker for disease activity. Intermediate-term modulators were defined as weekly climatic conditions hypothesized to modify the short-term effects of daily exposures. Associations were evaluated using conditional logistic and Poisson regression.

RESULTS:

The analysis included 7,032 adult patients with migraine residing in Be'er Sheva. Short-term exposure to nitrogen dioxide (NO₂) (odds ratio [OR] 1.41; 95% CI 1.13-1.77) and solar radiation (OR 1.23; 95% CI 1.07-1.42) was associated with an increased risk of emergency migraine-related encounters. Cumulative exposure to NO₂ was associated with a higher triptan use (incidence rate ratio [IRR] 1.10; 95% CI 1.00-1.21), as was cumulative particulate matter ≤2.5 µm (PM_2.5) exposure during the preceding quarter (IRR 1.09; 95% CI 1.00-1.19). Weekly climatic conditions modified short-term effects: high temperatures and low humidity during summer amplified NO₂-related risk (OR 2.18; 95% CI 1.06-3.30), whereas cold and humid winter weeks intensified the effect of PM_2.5 (OR 3.78; 95% CI 1.74-5.82).

DISCUSSION:

Short-term and cumulative exposure to ambient air pollution and climatic factors were associated with increased migraine activity. Although these findings support a layered model of environmental modulation of migraine activity, their generalizability is limited by the use of emergency health care encounters as a proxy outcome, underscoring the need for further research using complementary measures.

News (Medical) associated with Rizatriptan Benzoate

04 Jun 2026

·www.biospace.com

Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new SYMBRAVO ® data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting being held from June 4-7 in Orlando, FL. Details of the presentations are as follows: Title: SYMBRAVO (MoSEIC™ meloxicam and rizatriptan) for the Acute Treatment of Migraine: Post-hoc Composite Efficacy and Return to Function Endpoint Analysis from MOMENTUM Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET Lead Author: Richard Lipton, MD, Professor of Neurology and Director of the Montefiore Headache Center, Albert Einstein College of Medicine, NY Poster Number: T19 Title: Comparative Efficacy of SYMBRAVO vs. Gepants for Acute Treatment of Migraine: A Network Meta-Analysis Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET Lead Author: Stephanis Nahas, MD, MSEd, Professor of Neurology, Thomas Jefferson University, PA Poster Number: T24 Title: SYMBRAVO (MoSEIC meloxicam and rizatriptan) for the Treatment of Migraine: Sustained Pain Relief and Pain Freedom Among 2-Hour Responders in the Phase 3 MOMENTUM and MOVEMENT Trials Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET Lead Author: Chia-Chun Chiang, MD, Assistant Professor of Neurology at the Mayo Clinic, Rochester, MN Poster Number: T30 Title: SYMBRAVO (MoSEIC meloxicam and rizatriptan) for the Acute Treatment of Migraine: Post-hoc Composite Efficacy and Safety Endpoint Analysis of INTERCEPT and MOMENTUM Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET Lead Author: Fred Cohen, MD, Assistance Clinical Professor of Neurology, Icahn School of Medicine, Mount Sinai, NY Poster Number: T33 About Axsome Therapeutics Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, agitation associated with dementia due to Alzheimer’s disease, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, as well as multiple novel product candidates addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at and follow us on LinkedIn and X . Forward Looking Statements Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI ® , AUVELITY ® , and SYMBRAVO ® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Investors: Ashley Dong Senior Director, Investor Relations (929) 687-1614 adong@axsome.com Media: Darren Opland Senior Director, Corporate Communications (929) 837-1065 dopland@axsome.com

Phase 3NDA

04 Jun 2026

·axsometherapeuticsinc.gcs-web.com

Axsome Therapeutics Presents New SYMBRAVO® Data at the American Headache Society (AHS) 68th Annual Scientific Meeting

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new SYMBRAVO® data at the American Headache Society (AHS) 68th Annual Scientific Meeting being held from June 4-7 in Orlando, FL. Details of the presentations are as follows: Title: SYMBRAVO (MoSEIC™ meloxicam and rizatriptan) for the Acute Treatment of Migraine: Post-hoc Composite Efficacy and Return to Function Endpoint Analysis from MOMENTUM Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET Lead Author: Richard Lipton, MD, Professor of Neurology and Director of the Montefiore Headache Center, Albert Einstein College of Medicine, NY Poster Number: T19 Title: Comparative Efficacy of SYMBRAVO vs. Gepants for Acute Treatment of Migraine: A Network Meta-Analysis Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET Lead Author: Stephanis Nahas, MD, MSEd, Professor of Neurology, Thomas Jefferson University, PA Poster Number: T24 Title: SYMBRAVO (MoSEIC meloxicam and rizatriptan) for the Treatment of Migraine: Sustained Pain Relief and Pain Freedom Among 2-Hour Responders in the Phase 3 MOMENTUM and MOVEMENT Trials Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET Lead Author: Chia-Chun Chiang, MD, Assistant Professor of Neurology at the Mayo Clinic, Rochester, MN Poster Number: T30 Title: SYMBRAVO (MoSEIC meloxicam and rizatriptan) for the Acute Treatment of Migraine: Post-hoc Composite Efficacy and Safety Endpoint Analysis of INTERCEPT and MOMENTUM Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET Lead Author: Fred Cohen, MD, Assistance Clinical Professor of Neurology, Icahn School of Medicine, Mount Sinai, NY Poster Number: T33 About Axsome Therapeutics Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, agitation associated with dementia due to Alzheimer’s disease, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, as well as multiple novel product candidates addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at www.axsome.com and follow us on LinkedIn and X. Forward Looking Statements Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Investors: Ashley Dong Senior Director, Investor Relations (929) 687-1614 adong@axsome.com Media: Darren Opland Senior Director, Corporate Communications (929) 837-1065 dopland@axsome.com

Phase 3NDA

28 Oct 2025

·www.businesswire.com

Wisp Launches Comprehensive Migraine Care Vertical, Innovating Category with First-Ever, Asynchronous Care

NEW YORK--(BUSINESS WIRE)--Wisp, the largest pure play women's telehealth company in the U.S., today announced the launch of a dedicated migraine care vertical, consisting of online consults, prescription medications, and ongoing follow-up to help patients manage and prevent migraines. Wisp’s migraine specialists, certified by the National Headache Foundation, create customized treatment plans, expanding access to affordable, convenient care for patients wherever they are. Migraines affect one in five women — occurring nearly three times as often in women as in men — yet timely access to care remains a major barrier. On average, patients wait 34 days to see a neurologist, and in some cases, more than 90 days. Wisp’s new offering enables patients to receive care in 72 hours or less. “Migraine care is the natural next step for Wisp,” said Monica Cepak, CEO of Wisp. “Only one in four adults with episodic migraines receive diagnosis and treatment, and our patients continue to ask for treatment options. We’re delivering on our promise, with diagnoses made online, to democratize access to care, breaking down barriers so women can enjoy more pain-free days without the long wait times or high costs.” Wisp’s migraine care program includes: Migraine Consults ($60): Initial consults repeat every 6 weeks until the patient is on a stable dose. Quarterly Check-Ins ($30): Once stabilized, patients check in every 3 months for prescription refills. Prescriptions for Immediate Relief: Imitrex (Sumatriptan), Maxalt (Rizatriptan), Zomig ODT (Zolmitriptan). Anti-Nausea Medications: Zofran ODT (Ondansetron), Reglan (Metoclopramide). Preventive Medications: Topamax (Topiramate), Toprol XL (Metoprolol XL), Elavil (Amitriptyline), Lexapro (Escitalopram), Paxil (Paroxetine), Effexor ER (Venlafaxine ER). Patients begin with a $60 consult, complete a short intake form, and upload brief videos to help diagnose and assess eligibility. From there, a licensed provider reviews their medical history and intake to recommend a treatment plan, which may include immediate relief, anti-nausea, or preventive medications. Prescriptions are then sent the same day to the patient’s local pharmacy, with no insurance needed. “Migraines can be incredibly disruptive, but they are also very manageable with the right treatment plan,” said Dr. Jennifer Peña, Chief Medical Officer at Wisp. “Our approach provides patients with timely access to providers, tailored treatment options, and ongoing support so they feel empowered to take control of their health.” This launch follows Wisp’s recent expansion of its weight care vertical, furthering the company’s mission to provide affordable and accessible care for women across all life stages. From sexual and reproductive health to at-home diagnostics, fertility, menopause, to weight care and now migraine management, Wisp is continuing to build the most comprehensive platform designed for the unique needs of women. About Wisp: Wisp is the largest pure play women’s telehealth provider in the U.S., serving more than 1.5 million patients nationwide. Offering discreet, online care and a comprehensive range of first-to-market products, Wisp addresses women’s health needs across every stage of life—from birth control to fertility, menopause, STI testing, and more. Recognized by Fast Company as one of the Most Innovative Companies of 2023 and by Inc. as Best in Business 2024, Wisp is majority-owned by WELL Health Technologies Corp. Visit hellowisp.com or follow @hellowisp on social media.

100 Deals associated with Rizatriptan Benzoate

External Link

KEGG	Wiki	ATC	Drug Bank
D00675	Rizatriptan Benzoate	N02CC04	DB00953

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Migraine Disorders	Mexico	Merck Sharp & Dohme Corp.	21 Jan 1998

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Migraine With Aura	Phase 3	United States	Merck Sharp & Dohme Corp.	01 Apr 2007
Migraine Without Aura	Phase 3	United States	Merck Sharp & Dohme Corp.	01 Apr 2007
Acute migraine	Phase 3	-	Organon & Co.	01 Mar 1995
Post-Traumatic Headache	Clinical	United States	Merck Sharp & Dohme Corp.	01 Feb 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


FDA Manual	Not Applicable	Migraine Disorders	-	Rizatriptan 10 mg (Studies 1)	cbweccayzf(bmxcvozcid) = emcwzdghdz jyjbinjote (mpxoqqiloh )	Positive	14 Apr 2023
				Placebo (Studies 1)	cbweccayzf(bmxcvozcid) = vvwbskicfo jyjbinjote (mpxoqqiloh )
NCT00360282 (Pubmed \| Cochrane Database Syst Rev)	Not Applicable	Migraine Disorders	133	Triptans	ukhvpnxnuf(sbunmpfaej): risk ratio = 0.84 (95% CI, 0.66 - 1.07)	-	12 Apr 2023
				Placebo
NCT02447991 (CTgov)	Phase 2/3	Vertigo \| Dizziness \| Migraine Disorders	223	Placebo (Placebo)	hkgfesgmbz = ozjpkvyvgd vlwzlhjfwx (ghudtzqvrm, bqgclaugnu - fwkuuqehvy) View more	-	04 Nov 2021
				Rizatriptan (Rizatriptan)	hkgfesgmbz = blzziabyxi vlwzlhjfwx (ghudtzqvrm, crhiluoebj - xchkphwrwr) View more
NCT01086358 (CTgov)	Phase 4	Migraine Disorders	60	almotriptan+eletriptan+Treximet+rizatriptan+sumatriptan+zolmitriptan+triptan (Arm 1 - Triptan)	jzpaftffqf(cbplfyypws) = xkyioouwoy gslllhmxly (nhjfhwkgwt, djenoiqqki - bqmfsvcyol) View more	-	01 May 2018
				Naproxen Sodium (Treximet)+Sumatriptan (Arm 2 - Sumatriptan/Naproxen Sodium (Treximet) Arm)	jzpaftffqf(cbplfyypws) = estdulhedg gslllhmxly (nhjfhwkgwt, hzqzewqzce - qihlkeemnm) View more
NCT00360282 (CTgov)	Not Applicable	Migraine Disorders	36	Rizatriptan (Rizatriptan Visit)	qstvrmcadp(cmujnemsxx) = woegliexzc spilieuoyi (okyuiiegge, mspsalzmyo - mtfyjsxfxj) View more	-	08 Dec 2014
				Placebo (Placebo Visit)	qstvrmcadp(cmujnemsxx) = cfwidfticu spilieuoyi (okyuiiegge, phnvttxqym - xwmfnlfybl) View more
NCT01004263 (Pubmed \| Headache)	Phase 3	Migraine Disorders	674	Rizatriptan 5mg	jbwurwrjkx(pielpueufv) = wdmkfixgub aukivnkrkz (hphlvrapmg ) View more	-	01 Jan 2013
				Rizatriptan 10mg	jbwurwrjkx(pielpueufv) = lkogzjjkgn aukivnkrkz (hphlvrapmg ) View more
NCT01001234 (CTgov)	Phase 3	Acute migraine	1,382	Rizatriptan (Rizatriptan)	hrojnbvabo = jazdihmcvu mldjeswbyw (niuexyxqlo, ukccdgpszs - amhxfibfrs) View more	-	08 May 2012
				placebo (Placebo)	hrojnbvabo = ttcjgjnodg mldjeswbyw (niuexyxqlo, bgssulvhyy - qujtvdvwuz) View more
NCT01004263 (CTgov)	Phase 3	Migraine Disorders \| Migraine With Aura \| Acute migraine	674	rizatriptan benzoate	ymejgygmbh = ewobbhayyl twyrtfxams (pgzjklsmit, nmltkufqfc - ekunccqrgw) View more	-	04 May 2012
NCT00604812 (Pubmed \| Headache)	Phase 1	Migraine Disorders	-	Rizatriptan ODT 5mg	wzllasolau(ytyycslbmp) = mgyfswdjuw jgwzqlqyxd (lcjeckosgi, 48.60 - 66.09) View more	-	01 Apr 2012
				Rizatriptan 10mg ODT	wzllasolau(ytyycslbmp) = dhryxeihee jgwzqlqyxd (lcjeckosgi, 68.93 - 89.38) View more
Pubmed \| Headache	Phase 3	Acute migraine	108	Rizatriptan 10-mg ODT	dackxtornj(efhrdshbvc) = jabnywjsft oupczayodt (fchlommcwt ) View more	-	01 Jan 2012
				Placebo	dackxtornj(efhrdshbvc) = haluecsgxf oupczayodt (fchlommcwt ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis